SCHEMBL15577466

SCHEMBL15577466

CC(O)c1ncc(O)cc1Cl

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.36
KMT2A Q03164 3/20 0.36
HSD17B10 Q99714 2/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
MEN1 O00255 2/20 0.34
ALDH1A1 P00352 1/20 0.33
PKM P14618 1/20 0.33
GAA P10253 1/20 0.32
MB P02144 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
LMNA P02545 1/20 0.31
ESR1 P03372 1/20 0.31
PDE2A O00408 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17512693 0.82 MAPK1 (0.36) MAPK1KMT2ACYP3A4MEN1ALDH1A1
SCHEMBL31518746 0.82 LMNA (0.41) MAPK1KMT2ACYP3A4MEN1SMN1; SMN2
SCHEMBL21598707 0.78 PLAU (0.43) MAPK1KMT2AHPGDMEN1ALDH1A1
SCHEMBL336220 0.74 ALDH1A1 (0.37) MAPK1KMT2AMEN1ALDH1A1GAA
SCHEMBL28895677 0.74 KMT2A (0.62) MAPK1KMT2ACRHBPCRHR2MEN1
SCHEMBL21049712 0.73 KMT2A (0.38) MAPK1KMT2AMEN1GAASMN1; SMN2
SCHEMBL336116 0.73 KMT2A (0.39) MAPK1KMT2ACYP3A4MEN1GAA
SCHEMBL17512532 0.71 RORC (0.44) MAPK1KMT2AALDH1A1SMN1; SMN2LMNA
SCHEMBL19555715 0.70
SCHEMBL364169 0.69 HSD17B10 (0.37) KMT2AHSD17B10CYP3A4HPGDCRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2895488-B1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS MERCK SHARP & DOHME LLC (US) 2024-12-11 EP disclosed
US-10865216-B2 Tricyclic Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-12-15 US disclosed
US-10865216-B2 Tricyclic Gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2020-12-15 US disclosed
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME LLC 2015-09-03 US disclosed
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME LLC 2015-09-03 US disclosed
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME LLC 2015-09-03 US disclosed
EP-2895488-A1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS Trius Therapeutics, Inc. (US) 2015-07-22 EP disclosed
WO-2014043272-A1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS TRIUS THERAPEUTICS INC. (US) 2014-03-20 WO disclosed
WO-2014043272-A1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS TRIUS THERAPEUTICS INC. (US) 2014-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150246934-A1 TRICYCLIC GYRASE INHIBITORS TOP1, TOP2A, TOP2B MAPK1 2722/4885KMT2A 3484/4885HSD17B10 404/4885
US-10865216-B2 Tricyclic Gyrase inhibitors TOP1, TOP2A, TOP2B MAPK1 2722/4885KMT2A 3484/4885HSD17B10 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.